Analyzing...
Loading company...
JB Chemicals & Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and trade of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 5,095 full-time employees. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The firm is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). The company is involved in the provision of product development services. The firm offers varied products and dosage forms across therapeutic categories, which includes gastroenterology, hypertension, dermatology, nephrology, respiratory, virology, diabetes, wound care, anti-infectives, pharmacovigilance and nicotine replacement therapy (NRT). Its offers lozenges, which includes center-filled, soft-centered lozenges, center-filled, powder lozenges, herbal lozenges, and medicated lozenges. Its APIs products include Diclofenac Sodium, Diclofenac Diethylamine, Diclofenac Acid, Diclofenac Potassium, Nifedipine, Atenolol, Cilnidipine, and Ciprofloxacin HCl. The firm also owns Razel (Rousvastatin) franchise for the India and Nepal.
Excluded by gate
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹4,148 Cr revenue.
COGS 31.3%, employees 18.6%.
“revenues for the quarter were”
“We reiterate our guidance for operating margins between 27 to 29% for FY '26.”
“our guidance continues to be, growing better than the market two to 300 bps”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.1%▲ | 10.3% |
| ROCE | 21.9%▲ | 13.7% |
| Net Margin | 16.9%▲ | 7.6% |
| EBITDA Margin | 27.1%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
| Rev Growth 3yr | 10.0% | 10.0% |
| EPS Growth 3yr | 18.6%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4,148 Cr +5.9% | ₹3,918 Cr +12.5% | ₹3,484 Cr +10.6% | ₹3,149 Cr +29.9% | ₹2,424 Cr +18.7% | ₹2,043 Cr +15.1% | ₹1,775 Cr +8.0% | ₹1,643 Cr |
| Other Income | ₹60 Cr +57.0% | ₹38 Cr +2.8% | ₹37 Cr +274.9% | ₹10 Cr -74.7% | ₹39 Cr -65.1% | ₹112 Cr +121.8% | ₹51 Cr +22.3% | ₹41 Cr |
| Total Income | ₹4,208 Cr +6.4% | ₹3,956 Cr +12.3% | ₹3,521 Cr +11.5% | ₹3,159 Cr +28.2% | ₹2,463 Cr +14.3% | ₹2,155 Cr +18.1% | ₹1,825 Cr +8.4% | ₹1,685 Cr |
| COGS | ₹1,296 Cr -1.5% | ₹1,317 Cr +11.4% | ₹1,182 Cr +1.2% | ₹1,168 Cr +38.6% | ₹843 Cr +20.2% | ₹701 Cr +11.2% | ₹631 Cr +5.8% | ₹596 Cr |
| ₹3,228 Cr +5.2% | ₹3,069 Cr +10.8% | ₹2,770 Cr +6.4% | ₹2,604 Cr +33.0% | ₹1,959 Cr +25.7% | ₹1,558 Cr +6.2% | ₹1,467 Cr +4.9% | ₹1,398 Cr | |
| Profit Before Tax | ₹952 Cr +7.3% | ₹887 Cr +18.1% | ₹752 Cr +35.4% | ₹555 Cr +10.0% | ₹505 Cr -15.4% | ₹597 Cr +71.1% | ₹349 Cr +21.6% | ₹287 Cr |
| Exceptional Items | (₹27 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹10 Cr) | ₹0.00 Cr |
| ₹243 Cr +6.6% | ₹228 Cr +14.5% | ₹199 Cr +36.9% | ₹145 Cr +22.2% | ₹119 Cr -19.9% | ₹148 Cr +93.9% | ₹77 Cr -17.8% | ₹93 Cr | |
| Net Profit | ₹709 Cr +7.6% | ₹660 Cr +19.4% | ₹553 Cr +34.8% | ₹410 Cr +6.2% | ₹386 Cr -13.9% | ₹449 Cr +64.7% | ₹272 Cr +40.4% | ₹194 Cr |
| Profit (Owners) | ₹709 Cr +7.6% | ₹660 Cr +19.4% | ₹553 Cr +34.8% | ₹410 Cr +6.4% | ₹385 Cr -14.0% | ₹448 Cr +64.7% | ₹272 Cr +40.3% | ₹194 Cr |
| Other Comprehensive Income | ₹27 Cr +213.3% | ₹9 Cr ↑ Recovery | (₹15 Cr) -7.7% | (₹14 Cr) ↓ Decline | ₹4 Cr | ₹0.33 Cr ↑ Recovery | (₹15 Cr) -256.9% | (₹4 Cr) |
| EPS | ₹45.18 | ₹42.37 | ₹35.61 | ₹26.48 | ₹24.93 | ₹28.98 | ₹17.60 | ₹12.09 |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr | ₹15 Cr | ₹15 Cr | ₹15 Cr | ₹16 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Members of the Exchange are hereby informed that the trading in equity shares of JB Chemicals & Pharmaceuticals Limited shall be suspended w.e.f. July 17, 2026 (i.e., closing hours of trading on July ...
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Merger/HiveOff is 17-Jul-2026.
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
Torrent Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers...
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Change in Senior Management Personnel
The Exchange had sought clarification from JB Chemicals & Pharmaceuticals Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requir...
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Transcript
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Link of Recording
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Newspaper advertisement pertaining to financial results for the quarter and year ended March 31, 2026
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Newspaper advertisement for Postal Ballot
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
This is to inform you that the Compensation Committee of the Board of Directors of the Company has, on February 19, 2026, allotted 31,160 fully paid up equity shares of Re. 1/- each of the Company, to...
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Himanshu Ranvah as Other of the company w.e.f. February 06, 2026.